Parexel Expands Commercialization Capabilities With Dedicated Team To Help Biopharma Companies Demonstrate Product Value
Boston — PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has expanded its capabilities to provide biopharmaceutical companies with dedicated support for their commercialization goals. PAREXEL has fully integrated its commercialization services to help clients maximize regional and global market access opportunities. These solutions align reimbursement strategies with clinical development to gather the precise data required to demonstrate product value.
"More than ever our clients are faced with the acute need to prove that their products demonstrate value, in addition to safety and efficacy. Biopharmaceutical companies need to address commercialization goals as early as possible to develop products and acquire the right data to receive reimbursement approval in the most efficient way," said Gadi Saarony, Corporate Vice President and Worldwide Head, PAREXEL Consulting and Medical Communications Services.
According to Mr. Saarony, "We help clients prepare the product for the market and the market for the product through the alignment and integration of regulatory, clinical and commercialization strategies. Among the key advantages we offer to clients is that as a CRO we can draw on our experience developing products across all phases and a broad range of therapeutic areas to inform their commercialization strategies with meaningful scientific and clinical considerations. Through the expansion of our services, we are well positioned to help our clients optimize their products for efficient development and regulatory approval, as well as to achieve commercial success."
The PAREXEL commercialization services support the evolving needs of Health Economics and Outcomes Research (HEOR), Medical Affairs, Marketing, Reimbursement, and Managed Markets functions at biopharmaceutical company organizations. Clients benefit from the access PAREXEL has to a global network of Key Opinion Leaders (KOLs), as well as its database of global clinical trial experience, to assist in the development of effective commercialization strategies.
Designed to meet regional and global client needs, PAREXEL commercialization services include:
- Commercialization, reimbursement and market access strategy
- Publication strategy
- Global value and Academy of Managed Care Pharmacy (AMCP) dossier development
- Health outcomes analysis and economic modeling
The PAREXEL Commercialization Services team includes experts located throughout four continents who bring experience to biopharmaceutical companies in the areas of product management, market access, reimbursement and managed markets, as well as health outcomes, economics, and policy development and modeling. The team includes a cadre of former biopharmaceutical industry leaders, scientific researchers, regulators, and medical writers, as well as product development and management experts. These experts provide solutions for clients that are aligned to the product development and life cycle management processes.
PAREXEL helps biopharmaceutical companies to maximize the value of their products through launch and over the entire product lifecycle. PAREXEL provides commercialization solutions that deliver effective alignment of development and commercialization strategies as early as possible in the development process. For more information about commercialization services from PAREXEL visit: http://www.parexel.com/services-and-capabilities/consulting/reimbursement-market-access/.
SOURCE: PAREXEL International Corporation